Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 18,744 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: Acute Lymphoblastic Leukemia
Interventions: ADCT-402; Drug
Lead sponsor: ADC Therapeutics S.A.; Industry
Eligibility: 12 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 10
States / cities: La Jolla, California • New Haven, Connecticut • Atlanta, Georgia + 7 more

Conditions: Healhty, Overweight or Obesity
Interventions: BGM1812, Placebo; Drug
Lead sponsor: BrightGene Bio-Medical Technology Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Solid Tumor, Locally Advanced Solid Tumor, Metastatic Tumor
Interventions: 5 Azacytidine, Pembrolizumab, Nivolumab, Cemiplimab; Drug
Lead sponsor: Mohammed Milhem; Other
Eligibility: 18 Years to 99 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Spinal Cord Injury, Pain
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 85 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer, Renal Cancer, Urethral Cancer, Advanced Solid Tumor, Metastatic Castration-resistant Prostate Cancer, Solid Tumor, Adult
Interventions: Copper-64 labeled Granzyme B (64Cu-GRIP B), Positron Emission Tomography (PET); Drug · Procedure
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Myeloma
Interventions: Belantamab mafodotin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Subjects, Pharmacokinetics of ASP015K
Interventions: ASP015K, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Miami, Florida • Saint Paul, Minnesota

Conditions: Healthy Volunteer
Interventions: ASC43F; Drug
Lead sponsor: Gannex Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Advanced Colorectal Adenocarcinoma, Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
Interventions: Balstilimab, Biospecimen Collection, Botensilimab, Computed Tomography, Regorafenib; Biological · Procedure · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia
Interventions: Cyclophosphamide 500 MG, Cyclophosphamide 1000 MG, Cyclophosphamide 2000 MG, Cyclophosphamide 3000 MG, Cyclophosphamide 4000 MG; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Leukemia
Interventions: GNKG168; Drug
Lead sponsor: SBI Biotech Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 5
States / cities: La Jolla, California • Minneapolis, Minnesota • New Hyde Park, New York + 2 more

Conditions: Healthy
Interventions: RDEA3170 10 mg; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Advanced Solid Tumors
Interventions: E303; Drug
Lead sponsor: Samsung Bioepis Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Scottsdale, Arizona • Fairfax, Virginia

Conditions: AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma
Interventions: rituximab, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan, peripheral blood stem cell transplantation, filgrastim, laboratory biomarker analysis; Biological · Radiation · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Solid Tumors
Interventions: Vadimezan™; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 4
States / cities: Indianapolis, Indiana • Minneapolis, Minnesota • St Louis, Missouri + 1 more

Conditions: Breast Cancer, Breast Cancer Female, DCIS, Stage II Breast Cancer, Stage I Breast Cancer
Interventions: Partial Chest Wall Radiation Therapy; Radiation
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Healthy
Interventions: PF-06743649, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Her2 Amplified Solid Tumors, Metastatic Breast Cancer
Interventions: MM-111; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Los Angeles, California • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more

Conditions: Metastatic Cancer
Interventions: in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin, Cyclophosphamide, Fludarabine, Mesna; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Patients
Interventions: Empagliflozin, Dorzagliatin; Drug
Lead sponsor: Hua Medicine Limited; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Healthy Volunteers
Interventions: NaxRedy ™, Naloxone Hydrochloride Injection, USP; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose), Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose), Placebo (single-dose), Placebo (two-dose); Biological · Other
Lead sponsor: Meissa Vaccines, Inc.; Industry
Eligibility: 6 Months to 36 Months
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Phoenix, Arizona • La Mesa, California • Atlanta, Georgia + 9 more

Conditions: Prostate Cancer
Interventions: docetaxel, prednisone, Radical prostatectomy, Radiation therapy; Drug · Procedure · Radiation
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Dengue
Interventions: D1ME100 (dengue-1 premembrane/envelope DNA vaccine); Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Silver Spring, Maryland

Search by objective public record fields.

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Neurofeedback Treatment of Pain in Persons With Spinal Cord Injury (SCI)

64Cu-GRIP B in Patients With Advanced Malignancies

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K

Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects

Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy

Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia

A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

RDEA3170 AME Study

A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor

Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer

A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649

A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers

Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer

Drug Interaction Study Between Dorzagliatin and Empagliflozin

Bioavailability Study of Naloxone 5 Milligrams (mg) Intramuscular (IM) Autoinjector

Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer

Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine